These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1571 related items for PubMed ID: 18301895

  • 21. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, Silverman JA.
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [Abstract] [Full Text] [Related]

  • 22. Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone.
    Hoffmann J, Vitale I, Buchmann B, Galluzzi L, Schwede W, Senovilla L, Skuballa W, Vivet S, Lichtner RB, Vicencio JM, Panaretakis T, Siemeister G, Lage H, Nanty L, Hammer S, Mittelstaedt K, Winsel S, Eschenbrenner J, Castedo M, Demarche C, Klar U, Kroemer G.
    Cancer Res; 2008 Jul 01; 68(13):5301-8. PubMed ID: 18593931
    [Abstract] [Full Text] [Related]

  • 23. A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts.
    Polizzi D, Pratesi G, Tortoreto M, Supino R, Riva A, Bombardelli E, Zunino F.
    Cancer Res; 1999 Mar 01; 59(5):1036-40. PubMed ID: 10070960
    [Abstract] [Full Text] [Related]

  • 24. Specific targeting and killing activities of anti-P-glycoprotein monoclonal antibody MRK16 directed against intrinsically multidrug-resistant human colorectal carcinoma cell lines in the nude mouse model.
    Iwahashi T, Okochi E, Ariyoshi K, Watabe H, Amann E, Mori S, Tsuruo T, Ono K.
    Cancer Res; 1993 Nov 15; 53(22):5475-82. PubMed ID: 8106147
    [Abstract] [Full Text] [Related]

  • 25. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
    Roque DM, Bellone S, Buza N, Romani C, Cocco E, Bignotti E, Ravaggi A, Rutherford TJ, Schwartz PE, Pecorelli S, Santin AD.
    Am J Obstet Gynecol; 2013 Jul 15; 209(1):62.e1-9. PubMed ID: 23583215
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Combined treatment strategies for microtubule stabilizing agent-resistant tumors.
    Broggini-Tenzer A, Sharma A, Nytko KJ, Bender S, Vuong V, Orlowski K, Hug D, O'Reilly T, Pruschy M.
    J Natl Cancer Inst; 2015 Apr 15; 107(4):. PubMed ID: 25694444
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
    Chen LM, Liang YJ, Ruan JW, Ding Y, Wang XW, Shi Z, Gu LQ, Yang XP, Fu LW.
    J Pharm Pharmacol; 2004 Aug 15; 56(8):1061-6. PubMed ID: 15285852
    [Abstract] [Full Text] [Related]

  • 30. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
    Varvaresou A, Iakovou K, Gikas E, Fichtner I, Fiebig HH, Kelland LR, Double JA, Bibby MC, Hendriks HR.
    Anticancer Res; 2004 Aug 15; 24(2B):907-19. PubMed ID: 15161044
    [Abstract] [Full Text] [Related]

  • 31. Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts.
    Ramachandran C, Wellham LL.
    Anticancer Res; 2003 Aug 15; 23(3B):2681-90. PubMed ID: 12894558
    [Abstract] [Full Text] [Related]

  • 32. Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents.
    O'Reilly T, McSheehy PM, Kawai R, Kretz O, McMahon L, Brueggen J, Bruelisauer A, Gschwind HP, Allegrini PR, Lane HA.
    Cancer Chemother Pharmacol; 2010 Mar 15; 65(4):625-39. PubMed ID: 19784839
    [Abstract] [Full Text] [Related]

  • 33. Effect of pO2 on antitumor drug cytotoxicity on MDR and non-MDR variants selected from the LoVo metastatic colon carcinoma cell line.
    Lelong-Rebel I, Brisson C, Fabre M, Bergerat JP, Rebel G.
    Anticancer Res; 2008 Mar 15; 28(1A):55-68. PubMed ID: 18383825
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
    Bradley MO, Webb NL, Anthony FH, Devanesan P, Witman PA, Hemamalini S, Chander MC, Baker SD, He L, Horwitz SB, Swindell CS.
    Clin Cancer Res; 2001 Oct 15; 7(10):3229-38. PubMed ID: 11595719
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth.
    Jorgensen TJ, Tian H, Joseph IB, Menon K, Frost D.
    Cancer Chemother Pharmacol; 2007 May 15; 59(6):725-32. PubMed ID: 16967299
    [Abstract] [Full Text] [Related]

  • 38. Effects of patupilone (epothilone B; EPO906), a novel chemotherapeutic agent, in hepatocellular carcinoma: an in vitro study.
    Mok TS, Choi E, Yau D, Johri A, Yeo W, Chan AT, Wong C.
    Oncology; 2006 May 15; 71(3-4):292-6. PubMed ID: 17657173
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Reversal of P-gp-mediated multidrug resistance by Bromotetrandrine in vivo is associated with enhanced accumulation of chemotherapeutical drug in tumor tissue.
    Chen LM, Liang YJ, Zhang X, Su XD, Dai CL, Wang FP, Yan YY, Tao LY, Fu LW.
    Anticancer Res; 2009 Nov 15; 29(11):4597-604. PubMed ID: 20032409
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 79.